Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Treasury Shares (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has disclosed Treasury Shares for 7 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For Q4 2025, Treasury Shares rose 100.72% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 100.72%, while the annual FY2025 figure was $2.6 million, 100.72% up from the prior year.
  • Treasury Shares hit $2.6 million in Q4 2025 for Syndax Pharmaceuticals, up from $1.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.6 million in Q4 2025 and bottomed at $132333.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $634897.7, with a median of $392288.0 recorded in 2023.
  • Year-over-year, Treasury Shares surged 615.31% in 2021 and then skyrocketed 52.89% in 2023.
  • Syndax Pharmaceuticals' Treasury Shares stood at $132333.0 in 2021, then soared by 69.87% to $224788.0 in 2022, then surged by 131.08% to $519436.0 in 2023, then skyrocketed by 151.06% to $1.3 million in 2024, then skyrocketed by 100.72% to $2.6 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $2.6 million, $1.3 million, and $519436.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.